Synthetic Biologics (SYN) Offers Additional Positive Data from Two SYN-010 Phase 2s in IBS-C
Tweet Send to a Friend
Synthetic Biologics, Inc. (NYSE: SYN) reported detailed data supporting positive clinical outcomes from two previously reported Phase 2 clinical trials ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
